Inotuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a recombinant humanized monoclonal antibody directed against CD22 and a cytotoxic calicheamicin derivative. It is used as a targeted oncology therapeutic for certain forms of B-cell precursor acute lymphoblastic leukemia (B-ALL).
Unlike conventional small-molecule APIs, inotuzumab ozogamicin is a complex biological drug substance with multiple structural and quality attributes. Its characterization involves assessment of antibody identity, conjugation, drug-to-antibody ratio, purity, aggregation, potency and other critical quality attributes.
Inotuzumab ozogamicin specifically targets CD22, a cell-surface protein expressed on B-lineage cells. Following binding and internalization into the target cell, the conjugate releases its calicheamicin-derived cytotoxic payload.
The payload causes DNA damage, particularly double-strand DNA breaks, ultimately leading to death of the targeted leukemia cells.
The monoclonal antibody component binds to CD22 on B-lineage leukemia cells. The antibody-drug conjugate is subsequently internalized.
Inside the cell, the calicheamicin derivative is released and interacts with DNA, producing severe DNA damage and resulting in apoptosis of the targeted cell.
Inotuzumab ozogamicin is used in the development and manufacture of:
Inotuzumab ozogamicin is manufactured using biotechnology and bioconjugation processes rather than conventional small-molecule chemical synthesis alone.
Manufacturing and quality control involve antibody production, purification, conjugation with the calicheamicin-derived payload and extensive characterization of the resulting ADC.
Critical quality attributes can include:
Inotuzumab ozogamicin is a complex recombinant antibody-drug conjugate and is generally supplied as a sterile pharmaceutical drug substance or formulated product rather than as a conventional crystalline small-molecule powder.
Inotuzumab ozogamicin should be stored according to the manufacturer's validated conditions and applicable product specification. Temperature control and protection from inappropriate environmental exposure are important for maintaining the integrity of the antibody-drug conjugate.
Depending on the intended pharmaceutical application, documentation may include:
Inotuzumab ozogamicin is a CD22-targeted antibody-drug conjugate combining the specificity of a humanized monoclonal antibody with the potent cytotoxic activity of a calicheamicin-derived payload. Its targeted mechanism makes it an important biotechnology-derived therapeutic for selected B-cell precursor acute lymphoblastic leukemia applications.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |